Key Highlights

  • Teva Pharmaceutical (NYSE:TEVA) guides 2026 Revenue to USD 16.5 billion to USD 16.85 billion and non-GAAP EPS to USD 1.91 to USD 2.10, with adjusted EBITDA of USD 4.23 billion to USD 4.53 billion.
  • Second quarter revenue was about USD 4.1 billion, down 1 percent, and non-GAAP EPS was USD 0.02, or USD 0.63 excluding the Emalex-related impact.
  • Austedo U.S. revenue climbed 33 percent to USD 676 million. Ajovy grew 56 percent to USD 244 million, and Uzedy grew 43 percent to USD 77 million.
  • Results are due on Tuesday, November 3, 2026, at 7:00 a.m. ET, with a call at 8:00 a.m. ET, and the screener consensus for EPS is USD 0.73.

What Teva Is Expected To Report

Teva Pharmaceutical (NYSE:TEVA) reports third quarter results at 7:00 a.m. ET on November 3, 2026. The screener consensus is USD 0.73 per share, a large step up from the USD 0.02 reported in the second quarter, which was depressed by Emalex Acquisition expenses. Excluding that impact, second quarter EPS would have been USD 0.63, so a USD 0.73 consensus implies a clean recovery. The second quarter also showed a non-GAAP gross Margin of 55.4 percent, up 80 basis points, and free Cash Flow of USD 622 million, up 31 percent. A published headline also reported the shares at a new 12-month high on October 30, 2026. Teva also reaffirmed its operating profit, adjusted EBITDA and free cash flow outlook, so the third quarter is a test of margin recovery, not a guidance reset.

Innovative Drugs, Emalex And Debt

Teva is shifting from generics toward branded drugs, and the mix explains the story. Austedo guidance was raised to USD 2.45 billion to USD 2.6 billion, Ajovy to USD 850 million to USD 870 million, and Uzedy to USD 270 million to USD 290 million, while lower generic Revlimid sales offset the growth in total revenue. The June Emalex acquisition added USD 724 million of in-process research and development, which drove a GAAP net loss of USD 576 million. Net Debt was USD 12.9 billion, or 2.8 times EBITDA, against a target below 2 times, and long-term goals include a 30 percent non-GAAP operating margin.

Bull Case, Bear Case And Risks

In a bull case, Teva Pharmaceutical (NYSE:TEVA) delivers EPS at or above USD 0.73 and raises the Austedo range again, supporting the new 12-month high. In a bear case, Emalex expenses linger, generic erosion outpaces branded growth or EPS lands below USD 0.73, which would hit a stock that has already rallied. No options-implied move, share price or verified peer print was found, so no percentage range is given. Risks include generic price erosion, the cost of developing acquired assets, Leverage and concentration in a few branded products.

Where Things Stand

Teva Pharmaceutical (NYSE:TEVA) does guide up to USD 16.85 billion of 2026 revenue and faces a USD 0.73 EPS bar after a USD 0.02 quarter, though the USD 0.02 was mostly an Emalex acquisition effect, not weak operations. The balance of evidence favors branded growth, with Austedo, Ajovy and Uzedy all guided higher, against leverage and generic erosion. The next catalyst is the 7:00 a.m. ET release on November 3, 2026 and the 8:00 a.m. ET call, where margin recovery and any guidance change matter most. This is a preview, not a forecast of results.